Aboorva Kambiliampatti Sudhakar, MD
Endocrinology, Diabetes & Metabolism · Hattiesburg, MSNPI 1417339268
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $473 and has fallen 76.2% since, to $113 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MS, where the typical reported total is $4,678.
Across 68 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$316
- Insulet Corporation$183
- AbbVie$138
- Abbott$115
- Medtronic$107
- Xeris Pharmaceuticals, Inc.$70
- plus $420 from 14 others
What the payments were for
- Food & beverage$1,349100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $316 |
| Insulet Corporation | 5 | $183 |
| AbbVie | 8 | $138 |
| Abbott | 7 | $115 |
| Medtronic | 5 | $107 |
| Xeris Pharmaceuticals, Inc. | 3 | $70 |
| Amgen | 1 | $64 |
| Kaleo, Inc. | 3 | $53 |
| Lilly USA, LLC | 3 | $49 |
| GRT US Holding, Inc. | 2 | $33 |
| Corcept Therapeutics | 2 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $30 |
| IBSA Pharma Inc. | 2 | $29 |
| AstraZeneca | 2 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
How this compares
$1,349 in reported general payments places this provider in the 15th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 316 | $341,631 |
| JardianceEmpagliflozin | 189 | $153,460 |
| MounjaroTirzepatide | 115 | $127,251 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 124 | $84,752 |
| TradjentaLinagliptin | 125 | $73,262 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 76 | $70,079 |
| TrulicityDulaglutide | 62 | $68,904 |
| GlyxambiEmpagliflozin/Linagliptin | 105 | $68,801 |
| ForteoTeriparatide | 21 | $58,764 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 65 | $49,504 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $40,314 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $30,015 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $24,414 |
| Novolog FlexpenInsulin Aspart | 97 | $21,786 |
| SynjardyEmpagliflozin/Metformin Hcl | 32 | $21,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta, Glyxambi, Synjardy Xr | $23 | $457,267652 claims |
| Novo NordiskOzempic, Novolog | $316 | $344,074330 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Insulin Lispro | $49 | $262,354243 claims |
| Sanofi-aventis U.S. LLCLantus | $30 | $1,13714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Hattiesburg
- Richard GallowayHattiesburg$109K
- James PowellHattiesburg$88K
- Jaya NaranHattiesburg$3K
- Daniel McCallHattiesburg$1K
- Dana DaleHattiesburg$300
- Eric DyessJackson$885K
- Mark BorcheltGulfport$722K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Jeremy TaylorMadison$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.